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Abstract
Background: The study aimed to compare urinary symptoms in patients with clinically localized prostate cancer
after a combination of either low-dose-rate or high-dose-rate interstitial brachytherapy along with intensity-
modulated radiation therapy (LDR-ISBT + IMRT or HDR-ISBT + IMRT).
Methods: From June 2009 to April 2014, 16 and 22 patients were treated with LDR-ISBT + IMRT and HDR-ISBT +
IMRT, respectively. No patient from these groups was excluded from this study. The prescribed dose of LDR-ISBT,
HDR-ISBT, and IMRT was 115 Gy, 20 Gy in 2 fractions, and 46 Gy in 23 fractions, respectively. Obstructive and
irritative urinary symptoms were assessed by the International Prostate Symptom Score (IPSS) examined before and
after treatments. After ISBT, IPSS was evaluated in the 1st and 4th weeks, then every 2–3 months for the 1st year,
and every 6 months thereafter.
Results: The median follow-up of the patients treated with LDR-ISBT + IMRT and HDR-ISBT + IMRT was 1070.5 days
and 1048.5 days, respectively (p = 0.321). The IPSS-increment in the LDR-ISBT + IMRT group was greater than that in
the HDR-ISBT + IMRT between 91 and 180 days after ISBT (p = 0.015). In the LDR-ISBT + IMRT group, the IPSS took
longer time to return to the initial level than in the HDR-ISBT + IMRT group (in LDR-ISBT + IMRT group, the recovery
time was 90 days later). The dose to urethra showed a statistically significant association with the IPSS-increment in
the irritative urinary symptoms (p = 0.011). Clinical outcomes were comparable between both the groups.
Conclusions: Both therapeutic modalities are safe and well suited for patients with clinically localized prostate
cancer; however, it took patients longer to recover from LDR-ISBT + IMRT than from HDR-ISBT + IMRT. It is possible
that fast dose delivery induced early symptoms and early recovery, while gradual dose delivery induced late
symptoms and late recovery. Urethral dose reductions were associated with small increments in IPSS.
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Background
Brachytherapy is an established method in terms of both
efficacy and safety for patients with localized prostate
cancer [1, 2]. Interstitial brachytherapy (ISBT) for
localized prostate cancer can be administered as low-
dose-rate ISBT (LDR-ISBT) or high-dose-rate ISBT
(HDR-ISBT). It is well known that acute urinary symp-
toms develop shortly after brachytherapy; this is
reflected as an increase in the International Prostate
Symptom Score (IPSS) [3–6]. Several reports have de-
scribed the favorable efficacy of the combination of ISBT
with external beam radiation therapy (EBRT) for pros-
tate cancer [1, 2, 5, 7–10]. However, no studies have dir-
ectly compared the differences in the acute urinary
symptoms between these two ISBT techniques.
In our institution, a combination of intensity-
modulated radiation therapy (IMRT) with either LDR-
ISBT or HDR-ISBT has been applied for patients with
localized prostate cancer. The current study aimed to
compare the increments in IPSS after combination
EBRT along with either LDR-ISBT or HDR-ISBT.
Methods
Patient selection
Since June 2009, ISBT for patients with clinically local-
ized prostate cancer has been implemented in our insti-
tution. The T-stage was determined according to the
International Union against Cancer (UICC) [11]. The pa-
tients were classified according to the risk classification
of the National Comprehensive Cancer Network
(NCCN) guidelines [12]. Patients with intermediate-risk
prostate cancer with Gleason score of 4 + 3 and patients
with high-risk prostate cancer were treated by a combin-
ation of IMRT of 46 Gy in 23 fractions and either LDR-
ISBT of 115 Gy or HDR-ISBT of 20 Gy in 2 fractions. In
our institution, HDR-ISBT + IMRT was recommended
to patients with high-risk prostate cancer by treating
physician because favorable clinical results have been re-
ported after HDR-ISBT + IMRT for these patients [13,
14]. In contrast, for intermediate-risk patients, LDR-
ISBT + IMRT was recommended. Based on these sugges-
tions, the treatment method in each case was deter-
mined after discussions between the physicians and
patient.
In HDR-ISBT + IMRT, because the dose delivery of
HDR-ISBT requires 1–2 days, HDR-ISBT can be admin-
istered anytime during IMRT. In contrast, the dose de-
livery of LDR-ISBT requires several months; therefore, if
LDR-ISBT is performed before IMRT, IMRT is initiated
1–2 months after LDR-ISBT is completed. If IMRT is
performed earlier than LDR-ISBT, LDR-ISBT can be per-
formed immediately after the completion of the IMRT.
The numbers of patients for whom HDR-ISBT was per-
formed before IMRT, during IMRT, and after IMRT and
for whom LDR-ISBT was performed before IMRT and
after IMRT were counted. The patients treated by LDR-
ISBT alone were excluded from this study.
Technique of interstitial brachytherapy
The precise technique of LDR-ISBT has been described
elsewhere [4]. In brief, LDR-ISBT was performed with
125I seeds (Onco-Seed; Mihon Medi-Physics, Kobe,
Japan) of 0.394 mCi (14.6 MBq), 0.385 mCi (14.2 MBq),
or 0.416 mCi (15.4 MBq) under general anesthesia. No
margins were added around the prostate (clinical target
volume = planning target volume). At 1 month after
LDR-ISBT, post-plan dosimetry was performed in all pa-
tients [15–17]. Computed tomography (CT) images of
2-mm thickness were taken at 2-mm intervals with a
Foley catheter in place. T2-weighted magnetic resonance
images (MRI) were also obtained on the same day with a
Foley catheter and fused with the CT images to ensure
precise contouring of the prostate.
In HDR-ISBT, plastic catheters were inserted under
general and epidural anesthesias with the guidance of
TRUS using the perineal template. After catheter place-
ment, CT of the implanted region was performed by a
large bore CT simulator (Aquilion™, Toshiba, Tokyo,
Japan) with the patient lying in the lithotomy position.
As in LDR-ISBT, 2-mm thick CT images were taken
with 2-mm intervals. The prostate, urethra, rectum, and
bladder were contoured and stored in Oncentra® (ver.
4.1, Nucletron, Veenendaal, The Netherlands). As in the
case with LDR-ISBT, no margins were added to the
prostate. HDR-ISBT was carried out by 192Ir source re-
mote afterloading system (RALS, MicroSelectron HDR™,
Nucletron, Veennendaal, The Netherlands), with 192Ir
activity of approximately 10 Ci [18, 19]. The prescription
dose of HDR-ISBT was 20 Gy in 2 fractions with a 6-h
interval with patients lying on the bed during the
treatment.
The number of dwell positions in HDR-ISBT and 125I
seeds in LDR-ISBT was counted because the dose distri-
bution was related to these numbers.
Technique of intensity-modulated radiation therapy
IMRT was performed with either the Volumetric Modu-
lated Arc Therapy (VMAT) technique or Sliding-
window technique with a linear accelerator (Clinac iX;
Varian Medical Systems) using 15-MV photon beams.
Treatment planning for IMRT was based on CT images
of 2-mm slice thickness with 2-mm intervals obtained
with a large bore CT simulator and calculated by Eclipse
(ver. 8–11, Varian Medical Systems). MRI and CT im-
ages were fused to decide a target definition. However,
images from positron emission tomography (PET) were
not used for the target definition. Three different types
of plans were made as follows: (a) the clinical target
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volume (CTV) was defined as the prostate, whole sem-
inal vesicle and regional pelvic lymph nodes; (b) the
CTV was defined as the prostate and whole seminal
vesicle; and (c) the CTV was defined as the prostate plus
the proximal one-third of the seminal vesicle. Indica-
tions for plan (a) were as follows: patients having two of
the following high risk factors: T3a, level of prostate-
specific antigen (PSA) > 20 ng/dL, Gleason score ≥ 8, or
patients with T3b. The indication for plan (b) was pa-
tients with T3b. All the remaining patients were treated
by plan (c). The planning target volume (PTV) for the
prostate in the (a) plan was defined as the CTV plus
10 mm in the lateral, anterior, and cranio-caudal direc-
tions as well as 7 mm in the posterior direction. The
PTV in plans (b) and (c) plans was defined as the CTV
plus 5 mm in the left-right, anterior, and cranio-caudal
directions as well as 4 mm in the posterior direction. A
greater PTV margin was used in plan (a) because the pa-
tients were aligned using the bony structures to ensure
the proper positioning of the pelvic lymphatic node area.
In plan (b) or (c), on the other hand, a smaller PTV
margin was applied because the daily movement of the
prostate was tracked by abdominal ultrasonography or
an electric portal imaging device for patients with gold
markers in the prostate. The numbers of patients treated
as per the (a), (b), and (c) plans were counted for each
treatment.
The same dose constraints applied for patients treated
with IMRT alone (78 Gy in 39 fractions) were applied
for the patients included in our study (IMRT: 46 Gy in
23 fractions) with some modifications. The IMRT plan
of 46 Gy in 23 fractions was converted into an IMRT
plan of 78 Gy in 39 fractions to evaluate the dose con-
straints, and the following dose constraints were applied:
no more than 60 % and 35 % of the volume of the blad-
der wall were to receive a dose greater than 40 Gy and
70 Gy, respectively, and no more than 60 %, 35 %, 25 %,
and 1 % of the volume of the rectal wall were to receive
a dose greater than 40 Gy, 60 Gy, 70 Gy, and 80 Gy, re-
spectively. In all the patients, the dose for each organ at
risk (OAR) passed the dose constraints while maintain-
ing the coverage of PTV.
Dose evaluation
Dose distribution of the LDR-ISBT, HDR-ISBT, and
IMRT was calculated with VariSeed™, Oncentra™, and
Eclipse™, respectively. In order to compare the dose dis-
tributions of LDR-ISBT + IMRT with that of HDR-ISBT
+ IMRT, the equivalent doses in 2 Gy/fraction (EQD2)
for IMRT, LDR-ISBT, and HDR-ISBT were calculated by
rewriting the DICOM-RT by using Python (x,y)™ (ver.
2.7.6). The EQD2 calculation of the LDR-ISBT was given
by equation (1) [20], and that of HDR-ISBT as well as







EQD2 ¼ nd d þ α=βð Þ2þ α=βð Þ ð2Þ
where D is the accumulated dose, R0 is the initial dose
rate, λ is the radioactive decay constant, μ is the rate of
repair of sub-lethal damage, n is the number of fractions,
and d is the dose per fraction. Because acute urethral
complications were investigated in this study, the α/β ra-
tio used in this study was 10 Gy, μ was 0.462 h−1, and λ
was 4.86 × 10−4 h−1 [21].
After the rewriting of the DICOM-RT, the DICOM-
RT was transferred from each treatment planning system
(TPS) to the MIM Maestro™ software (ver. 6, MIM soft-
ware, OH, USA). Then, the LDR-ISBT dose and the
IMRT dose or the HDR-ISBT dose and IMRT dose were
summed using MIM Maestro™.
The urethra was contoured as the outer rim of the
Foley catheter from the bladder neck to the most caudal
prostate that could be found. In addition to the urethra,
the basal urethra was defined as the most proximal one-
third of the prostatic urethra in proximity to the bladder
trigone and contoured as an OAR for this study. Al-
though the relationship between the dose to the bladder
trigone and increments in the IPSS was investigated by
the MSKCC group [22], it was difficult to evaluate the
dose to the bladder trigone in this study, because the pa-
tient’s position in the CT-images at HDR-ISBT did not
correspond to those of IMRT, and the CT coverage dur-
ing ISBT was not adequate in the cranial direction in
order to identify the ureteral orifices. Therefore, in this
study, the base of the urethra was evaluated as a surro-
gate structure for the bladder trigone.
The registration of anatomic structures contoured on
different CT series of ISBT and IMRT was performed on
the basis of the contouring of the urethra and prostate
by Eclipse™. The evaluations of the cumulative dose to
the whole urethra and the base of the urethra were per-
formed by the CT image for the IMRT planning. The
dose-volume histogram (DVH) was examined in 0.1 Gy
steps. In IMRT planning, the dose to the urethra was an-
alyzed to evaluate the variances in the dose to the
urethra.
Urinary symptoms
The increment in IPSS was defined as the difference be-
tween the IPSS before (initial IPSS) and after the ISBT.
Recovery time was defined as the time from the comple-
tion of the radiation therapy to the time point when the
difference between the initial and after-the-treatment
IPSS values lost its significance after the maximum
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increment in the IPSS. After ISBT, in general, IPSS was
evaluated in the 1st and 4th weeks, then every 2–3
months for the 1st year, and every 6 months thereafter.
The IPSS consists of 7 questions classified into either
obstructive (Items 1, 3, 5, and 6) or irritative (Items 2, 4,
and 7) symptoms [23]. Therefore, not only IPSS as a
total score (t-IPSS) but also the scores for obstructive
symptoms (o-IPSS) and irritative symptoms (i-IPSS)
were also investigated separately.
Because Ghadjar et al. showed that an increment in
IPSS greater than 10 points from the initial IPSS was re-
lated to the dose to the bladder trigone [22], the analysis
in the present study included the following endpoints:
increment from initial t-IPSS + 10 endpoint, the initial o-
IPSS + 5 endpoint, and the initial i-IPSS + 5 endpoint.
Statistical analysis
The relationship between clinical and treatment vari-
ables and the increment in IPSS was analyzed by uni-
variate analysis. The variance was analyzed by
Shapiro-Wilk test to detect the variance of distribu-
tion. As a result, if the variance of distribution of
each IPSS was normal, we used Student’s t-test. On
the other hand, if the variance of distribution was not
normal, we used the Mann–Whitney-U test. The t-
test was used to compare continuous variables, and
Pearson χ2 test was used to compare categorical vari-
ables. Time to overall survival (OS), biochemical pro-
gression free survival (BPFS), and progression free
survival (PFS) were analyzed with Kaplan-Meier
method, and the log-rank test was performed. The bio-
chemical control rate was defined with using Phoenix cri-
teria [24]. A p-value < 0.05 was considered as statistically
significant. All continuous clinical variables and DVH pa-
rameters were dichotomized at the median value and ana-
lyzed. Multiple logistic regression analysis was performed
using the variables that showed significant difference in
the univariate analysis.
This retrospective study was approved by the institu-
tional review board of the National Cancer Center
(2014–223). The informed consent was not taken from
each patient because this retrospective study was ap-
proved by institutional ethical committee and it was de-
cided that the ethic committee waived taking informed
consent from each patient.
Results
Patients
From June 2009 through April 2014, 16 and 22 patients
were treated with the combination of LDR-ISBT plus
IMRT and HDR-ISBT plus IMRT (LDR-ISBT + IMRT or
HDR-ISBT + IMRT), respectively. No patient was ex-
cluded from this study. Clinical characteristics of the pa-
tients are summarized in Table 1. Three patients in the
LDR-ISBT + IMRT group received neoadjuvant androgen
deprivation therapy (ADT), while 11 in the HDR-ISBT +
IMRT group received ADT. After ISBT, ADT was
stopped unless patients experienced biochemical or clin-
ical recurrence. In the HDR-ISBT + IMRT group, the
number of patients for whom HDR-ISBT was performed
before IMRT, during IMRT, and after IMRT was 11, 6,
and 5, respectively. The pretreatment level and incre-
ment in i-IPSS showed significant differences among
three treatment sequencings (p < 0.05). In the LDR-
ISBT + IMRT group, the number of patients for whom
LDR-ISBT was performed before IMRT and after IMRT
was 14 and 2, respectively. There was no significant dif-
ference in the pretreatment level and increments in the
t-IPSS, o-IPSS, and i-IPSS (p > 0.05). The number of
dwell positions in HDR-ISBT and the 125I seeds in LDR-
ISBT was 265.7 ± 103.2 and 66.1 ± 16.1 (p < 0.001), re-
spectively. Among the patients who received HDR-ISBT
+ IMRT, the number of patients with CTV (a), (b), and
(c) was 11, 8, and 3, respectively, while among the pa-
tients who received LDR-ISBT + IMRT, it was 1, 12, and
3, respectively. In the HDR-ISBT + IMRT group, the pre-
treatment level of i-IPSS showed a significant difference
among the 3 CTV definitions (p = 0.04). However, an in-
crement in t-IPSS, o-IPSS, and i-IPSS showed no signifi-
cant differences among the 3 CTV definitions (p > 0.05).
Among the patients who received LDR-ISBT + IMRT,
there were no significant differences in the pretreatment
level or the increments in t-IPSS, o-IPSS, and i-IPSS
among the 2 CTV definitions ((b) and (c); p > 0.05).
Urinary symptoms
The mean initial t-IPSS of the LDR-ISBT + IMRT and
HDR-ISBT + IMRT groups was 9.48 and 9.53, respect-
ively (p = 0.983). The mean initial o-IPSS of the LDR-
ISBT + IMRT and HDR-ISBT + IMRT groups was 5.31
and 4.64 (p = 0.677), while the mean initial i-IPSS was
4.17 and 4.91, respectively (p = 0.429). The t-IPSS, o-
IPSS, and i-IPSS in the HDR-ISBT + IMRT group
reached its maximum 0–90 days after HDR-ISBT, while
that in the LDR-ISBT + IMRT group reached its max-
imum 91–180 days after LDR-ISBT. A significant differ-
ence between the LDR-ISBT + IMRT and HDR-ISBT +
IMRT was found in the increments in the t-IPSS during
91–180 and 181–270 days (Fig. 1a; p = 0.015 and 0.037,
respectively), and in the increment in the i-IPSS (p =
0.013,- 0.015) during 91–180, 181–270, 271–360, and
541–630 days (Fig. 1c; p = 0.001, 0.027, 0.013, and 0.015,
respectively). However, no significant differences were
noted in the increments in the o-IPSS (Fig. 1b). In t-
IPSS, the recovery time in the LDR-ISBT + IMRT and
HDR-ISBT + IMRT groups were 181–270 days and 91–
180 days, respectively. In o-IPSS, the recovery time in
the LDR-ISBT + IMRT and HDR-ISBT + IMRT groups
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were 181–270 days and 91–180 days, respectively
(Fig. 1b). In i-IPSS, the recovery time of the LDR-ISBT
+ IMRT and HDR-ISBT + IMRT groups were 361–450
days and 91–180 days, respectively (Fig. 1c).
With respect to the DVH, a significant difference was
found in both the volume of the urethra and base of the
urethra receiving more than 69.4 Gy in EQD2 and
74.3 Gy in EQD2 between the patients receiving LDR-
ISBT + IMRT and HDR-ISBT + IMRT (Fig. 2a and b, p <
0.05). The dose to the prostate delivered by the IMRT
component in LDR-ISBT + IMRT and HDR-ISBT +
IMRT was 46.5 ± 1.0 Gy and 46.7 ± 1.1 Gy ((mean dose)
± σ; p = 0.311), respectively.
The results for the univariate analysis for the incre-
ments from initial t-IPSS + 10 endpoint, the initial o-
IPSS + 5 endpoint, and the initial i-IPSS + 5 endpoint are
summarized in Table 2. The D50% of the urethra was as-
sociated with the initial t-IPSS + 10 and the initial i-IPSS
+ 5 endpoints (p = 0.024, and 0.031, respectively). The
brachytherapy technique, the D50% of the base of the ur-
ethra, the V90 of the urethra and base of the urethra,
and the V100 of the urethra were also associated with the
i-IPSS +5 endpoint (p < 0.05).
The results of the multiple logistic regression analysis
are shown in Table 3. The D50% of the urethra was a pre-
dictor for the initial i-IPSS + 5 (p = 0.011).
None of the patients in this study experienced urinary
tract infection.
Rectal symptoms
In the HDR-ISBT + IMRT and LDR-ISBT + IMRT
groups, 0 and 2 patients, respectively, developed grade 2
rectal bleeding according to Common Toxicity Criteria
(p = 0.088).
Clinical outcome
The 3-year OS rate, BPFS rate, and PFS rate for all the
patients included in the current study were 97.4 %,
Table 1 Patient characteristics
HDR-ISBT+IMRT LDR-ISBT+IMRT p value
n(%) n(%)
Age[years], median(range) 67.8 (54.5-81.4) 65.8 (52.6-78.8) 0.498
Stage 0.867
■T1b 1 (4.5) 1 (6.3)
■T1c 11 (50) 9 (56.2)
■T2a 2 (9.1) 1 (6.3)
■T2b 2 (9.1) 3 (18.8)
■T2c 2 (9.1) 1 (6.3)
■T3a 2 (9.1) 1 (6.3)
■T3b 2 (9.1) 0 (0)
Initial PSA 0.061
■<10 7 (31.8) 8 (50)
■ 10-20 8 (36.4) 7 (43.7)
■>20 7 (31.8) 1 (6.3)
Gleason Score 0.029*
■<7 0 (0) 0 (0)
■7 17 (77.3) 16 (100)
■>7 5 (22.7) 0 (0)
Risk grouping (NCCN classification) 0.031*
■ Low 0 (0) 0 (0)
■ Intermediate 12 (54.5) 14 (87.5)
■ High 10 (45.5) 2 (12.5)
Baseline t-IPSS, median(range) 8.3 (1.0-23.0) 6.75 (1.5-23.0) 0.982
ADT 10 (45.5) 3 (18.8) 0.087
Folow-up [days], median(range) 1048.5 (409–2199) 1070.5 (617–2199) 0.321
Prostate volume [cc], median(range) 40.8(17.5-94.5) 33.1(13.6-73.8) 0.12
Abbreviations: HDR-ISBT + IMRT combination of HDR-ISBT and intensity-modulated radiation therapy, LDR-ISBT + IMRT combination of LDR-ISBT and intensity-
modulated radiation therapy, ADT androgen deprivation therapy, NCCN National Comprehensive Cancer Network
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89.5 %, 92.1 %, respectively (Fig. 3(a)). In the HDR-ISBT
+ IMRT group, only 1 patient died. In the LDR-ISBT +
IMRT group, no patient died during the study period.
The number of patients who suffered biochemical failure
(PSA failure) in the HDR-ISBT + IMRT and LDR-ISBT +
IMRT groups was 4 and 0, respectively. The number of
patients with clinical recurrence in the HDR-ISBT +
IMRT and LDR-ISBT + IMRT groups was 3 and 0,
respectively. In the HDR-ISBT + IMRT and LDR-ISBT +
IMRT groups, the 3-year OS, BPFS, and PFS were
100 %, 86.4 %, and 90.9 % and 100 %, 100 %, and 100 %,
respectively (Fig. 3(b), (c), and (d); p = 0.264, 0.057, and
0.110, respectively). Figure 3 shows the Kaplan-Meier
curves for OS, BPFS, and PFS.
Discussion
In this study, the direct comparison of the IPSS between
the LDR-ISBT + IMRT and HDR-ISBT + IMRT groups
showed that the increments in IPSS among the patients
receiving LDR-ISBT + IMRT occurred later than that in
the HDR-ISBT + IMRT group. In the LDR-ISBT + IMRT
group, the maximal increase in the t-IPSS occurred
around 90–180 days after LDR-ISBT and the IPSS
returned to the pretreatment level between 181 and 270
days. The timing of the maximal increase in IPSS in the
LDR-ISBT group was in accordance with previous find-
ings, although that study focused on patients treated
only with LDR-ISBT [4]. Murakami et al. reported that
the timing of the maximum increase in t-IPSS in LDR-
ISBT was 3 months after ISBT [4]; therefore, it was
likely that the maximum increase in the LDR-ISBT +
IMRT group was observed later than that in LDR-ISBT
alone because IMRT was additionally performed. The
maximum increments in t-IPSS in the study by
Murakami et al. and in the present study were 10.7 ± 6.9
Fig. 2 Dose volume histogram. a Dose volume histogram of the
urethra, and b Dose volume histogram of the base of urethra
Fig. 1 Time change of the International Prostate Symptom Score
(IPSS). a A total score after interstitial brachytherapy (t-IPSS), and
b the obstructive symptom (o-IPSS), and c the irritative symptom
(i-IPSS). The * indicates a period that has a statistically
significant difference
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and 8.6 ± 9.2 ((mean) ± (1 SD)) [4], respectively. In con-
trast, in the HDR-ISBT + IMRT group, the maximal in-
crease in the IPSS occurred around 0–90 days after
HDR-ISBT and the IPSS returned to the pretreatment
level between 91 and 180 days. Mahmoudieh et al. re-
ported that the timing of the maximum increase in t-
IPSS in HDR-ISBT was 6 weeks, and the t-IPSS returned
to the pretreatment level after 6 months [5]. These re-
sults corresponded with those of the current study. The
maximum increment in t-IPSS in the study by Mahmou-
dieh et al. was approximately 4 (mean), while that in our
study was 7.1 ± 6.0 ((mean) ± (1 SD)). In LDR-ISBT,
98.6 % of the prescription dose is delivered over a period
as long as 1 year and 65.5–87.8 % of the dose delivery is
completed by 91–180 days after the initiation of LDR-
ISBT. In contrast, in HDR-ISBT, the prescription dose is
delivered within only 1–2 days. This huge difference in
the total duration of dose delivery between LDR-ISBT
and HDR-ISBT may have an enormous influence on the
differences observed in the timing of increment and re-
covery of IPSS in patients treated with LDR-ISBT and
HDR-ISBT.
The structure of the urethra on the CT series during
IMRT was not contoured precisely because the Foley
catheter was not inserted when CT images for IMRT
were taken. However, this issue was not important be-
cause in LDR-ISBT + IMRT and HDR-ISBT + IMRT
both, the dose to the prostate delivered by the IMRT
Table 3 The multiple logistic regression analysis for increment of IPSS. The multiple logistic regression analysis of whether t-IPSS
incresased by ten or over ten points during 91–180 days after ISBT. Similary, i-IPSS increment of five or over five points during the
same time period was analyzed
IPSS Factor Odds ratio (95 % of confidence level) p value
t-IPSS + 10 D50 % of urethra 1.021 (1.001-1.041) 0.035*
D50 % of urethra 1.039 (1.009-1.069) 0.011*
D50 % of base of urethra - 0.868
i-IPSS + 5 V90 of urethra - 0.657
V90 of base of urethra - 0.411
V100 of urethra - 0.427
Brachytherapy technique - 0.100
t-IPSS + 10 (D50 % of urethra): Model x test: p<0.001, Determine predictive value: 80.6 %; i-IPSS + 5 (D50 % of urethra): Model x test: p<0.001, Determine predictive
value: 90.3 %
Abbreviations: IPSS international Prostate Symptom Score, t-IPSS total score of IPSS, i-IPSS total score of IPSS about irritative symptom, Dx% minimum dose
delivered to x% of the organ volume, Vx proportion of volume receving x Gy. The Gy indicates the dose which was converted into the EQD2
The * indicates a variable that has a significant difference
Table 2 The univariate analysis for IPSS increment. The univariate analysis of wheather t-IPSS increased by ten or
over ten points during 91–180 days after ISBT. Similary, o-IPSS and i-IPSS increment of five or over five points during the same time
period was analyzed
p value
Factor t-IPSS+10 o-IPSS+5 i-IPSS+5
Age <66.17 vs >66.17 0.838 0.959 0.253
Prostate volume <36.7 ml vs >36.7 ml 0.681 0.457 0.750
Risk group intermediate vs high 0.820 0.540 0.318
Initial PSA <11.84 vs >11.84 1.000 0.609 0.124
Baseline t-IPSS <7.67 vs >7.67 0.217 0.400 0.253
ADT yes vs no 1.000 0.505 0.472
Brachytherapy technique LDR-ISBT vs HDR-ISBT 0.066 0.193 0.010*
D50 % of urethra <95.65 Gy vs >95.65 Gy 0.024
* 0.101 0.031*
D50 % of base of urethra <95.70 Gy vs >95.70 Gy 0.152 0.397 0.031
*
V90 of urethra <85.32 % vs >85.32 % 0.152 0.397 0.031*
V90 of base of urethra <75.01 % vs >75.01 % 0.152 0.397 0.031
*
V100 of urethra <17.05 % vs >17.05 % 0.217 0.535 0.005*
Abbreviations: ADT androgen deprivation therapy, IPSS international Prostate Symptom Score, t-IPSS total score of IPSS, o-IPSS + 5 total score of IPSS about
obstructive symptom, i-IPSS + 5 total score of IPSS about irritative symptom, Dx% minimum dose delivered to x% of the organ volume, Vx proportion of volume
receiving x Gy. The Gy indicates the dose which was converted into the EQD2
The * indicates a variable that has a significant difference
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component was approximately the same (p = 0.311) be-
cause the urethra and base of the urethra was defined as
the prostatic urethra. As a result, the contouring uncer-
tainty of the urethra could be ignored.
The IPSS consists of two distinct urinary symptom
categories, i.e., obstructive and irritative symptoms, and
the present study assessed both categories in detail. In
the current study, multivariate analysis revealed that the
increments in the IPSS related to irritative symptoms,
for which the responsible organ was supposed to be the
bladder, were related to the D50 % of the urethra. In con-
trast, univariate analysis demonstrated that the D50 % of
the base of the urethra, the V90 of the urethra and base
of the urethra, the V100 of the urethra, and the brachy-
therapy technique were related with i-IPSS + 5. Member
of the patient groups in the D50 % of the base of the ur-
ethra and the V90 of the base of the urethra were the
same. As a result, the same p-value was calculated. On
the other hand, member in the D50 % of the urethra and
the V90 of the urethra was different from those groups,
and member in the D50 % of the urethra was also differ-
ent from that in V90 of the urethra. The D50 % of the ur-
ethra was a unique patients group. Therefore, although
p-value was the same in i-IPSS + 5, the D50 % of the ur-
ethra in i-IPSS + 5 alone showed a significant difference
in multivariate analysis. Although the base of the urethra
was not be found to be a predictive factor in multivariate
analysis, it showed a significant difference in the univari-
ate analysis. Thus, since the base of the urethra was
intended to be used as a surrogate structure for the
bladder trigone in the current study, this finding might
be in line with the results of Ghadjar et al. that the blad-
der trigone was responsible for the increment in IPSS
after IMRT [22]. Further, the D50% of the urethra was re-
lated to the increment in t-IPSS + 10 points, although
Ghadjar et al. reported that a maximal dose to the blad-
der trigone of over 90.9 Gy was related to the increment
of t-IPSS + 10 points [22]. Taken together, these results
suggests that the severity of acute urinary morbidities, as
represented by increments in IPSS was lowered by
reducing the dose to the urethra (Figs. 1 and 2, and Ta-
bles 2 and 3). This finding is in line with anatomical dis-
tribution of the autonomic nerve of the bladder.
Recently, Sprandling et al. reported using cadavers with
3-dimensional image reconstruction that bladder auto-
nomic nerves are located in the posterior region of the
prostatic urethra in the male [25]. Technically, in HDR-
ISBT, the dose to the urethra can be easily decreased be-
cause the dwell positions in HDR-ISBT are more than
the number of 125I seeds used in LDR-ISBT.
Favorable clinical results have been reported for both
LDR-ISBT + EBRT and HDR-ISBT + EBRT for prostate
cancer [7, 9]. Similarly, our results indicated no signifi-
cant difference in the clinical outcomes, i.e., OS, BPFS,
and PFS, between the LDR-ISBT + IMRT and HDR-
ISBT + IMRT groups (Fig. 3). The advantage of LDR-
ISBT is the short procedure time, while its disadvantages
are the long recovery time and the trend of more severe
acute urinary symptoms as compared to HDR-ISBT, as
shown in the present study. The advantages of HDR-
ISBT include the short recovery time and less severe
urinary symptoms; moreover, HDR-ISBT easily allows
dose adjustment for each organ. However, the disadvan-
tage of HDR-ISBT is that patients are confined to the
hospital bed for at least 6-h while the applicator needles
are in place. Thus, both the ISBT techniques have their
advantages and disadvantages that are not related to
overall clinical outcomes; therefore, the treatment
method should be selected in each case after detailed
discussion between the attending physician and the
patient.
This study had certain limitations (e.g., retrospective
analysis, small sample size, different sequencing of ISBT,
different distributions of risk groups, different Gleason
scores, differences in the distributions of ADT, and no
standardized protocol). It has been reported that various
parameters (e.g., initial IPSS or neoadjuvant hormone
therapy) are related to increments in IPSS. However,
these relatiofnships have not been established thus far
[4, 26]. In the present study, even if the TNM stage, risk
Fig. 3 Kaplan-Meier curves of a Survival, b Overall survival, c Biochemical progression free survival, and d Progression free survival
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categories, and Gleason scores differed between the two
groups, our aim was not to compare clinical results but
rather the treatment-related toxicities between the two
groups; therefore, it was considered feasible to compare
groups of patients with different backgrounds. Moreover,
it was likely that differences in the CTV did not influ-
ence the increments in IPSS. However, it would not be
appropriate to discuss the relationship between different
CTV definitions and increments in IPSS because only 1
patient in the LDR-ISBT + IMRT group was treated for
plan (a). In the different sequencings, although the in-
crements in i-IPSS showed significant differences among
the three sequencing in the HDR-ISBT + IMRT group, it
was likely that the significant differences pertained to
the significant differences in the pretreatment level of i-
IPSS. In the LDR-ISBT + IMRT, there was no significant
difference in pretreatment levels or increments in t-
IPSS, o-IPSS, and i-IPSS (p > 0.05). Therefore, the differ-
ence in treatment sequencing may not have influenced
the increments in IPSS; however, we did not consider it
appropriate to discuss this relationship because of the
limited number of patients treated with IMRT followed
by LDR-ISBT.
Conclusions
This study was the first to perform a direct comparison
of IPSS between LDR-ISBT and HDR-ISBT for patients
with localized prostate cancer. Increments in IPSS in the
HDR-ISBT + IMRT group occurred sooner than in the
LDR-ISBT + IMRT group. Further, patients treated with
HDR-ISBT + IMRT showed a shorter recovery time than
those treated in with LDR-ISBT + IMRT with respect to
urinary symptoms. It is possible that fast dose delivery in-
duced early symptoms and early recovery, while gradual
dose delivery induced late symptoms and late recovery.
Our findings also indicated that the increment in the total
IPSS and the IPSS concerning the irritative symptoms was
related to the D50% of the urethra. Therefore, urethral dose
reductions were associated with small increments in IPSS.
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